RxDoctor Payments DataLook up a doctor →

Scott Tagawa, MD

Hematology & Oncology · New York, NYNPI 1245258045

Payments from drug & device makers

$10,335,111in general payments, 2019–2025

Across 664 payments — averaging $15,565 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$5.4M
  • Novartis$1.6M
  • Janssen Research & Development, LLC$1.2M
  • Seagen Inc.$571K
  • AstraZeneca$372K
  • Gilead$253K
  • plus $976K from 36 others
$19,865in research payments, 2019–2025

Across 22 payments — averaging $902.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$17K
  • Novartis$2K
  • Novartis Pharma AG$609
  • Gilead$121

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck78$5,382,539
Novartis36$1,596,045
Janssen Research & Development, LLC47$1,184,216
Seagen Inc.74$570,954
AstraZeneca53$372,427
Gilead35$252,924
Bioxcel Therapeutics, Inc.4$209,845
Amgen19$182,843
Genentech, Inc.3$115,751
Pfizer60$111,181
Pharmaand GmbH2$57,676
Astellas Pharma Global Development14$43,543
Johnson & Johnson33$38,027
Clovis Oncology, Inc.19$24,845
Telix Pharmaceuticals47$22,684
Bayer18$20,776
E.r. Squibb & Sons, L.L.C.4$16,911
GE HealthCare7$15,865
Sanofi12$14,992
Lantheus Medical Imaging, Inc.12$13,158
Astellas Pharma US Inc6$12,276
Advanced Accelerator Applications4$9,421
Regeneron8$7,690
Janssen Scientific Affairs, LLC12$7,342
Progenics Pharmaceuticals, Inc.13$7,310
Janssen Global Services, LLC5$6,104
AbbVie5$6,004
EMD Serono, Inc.2$5,820
Daiichi Sankyo Inc.4$4,297
Immunomedics, Inc.1$4,100
Exelixis Inc.11$4,024
Eli Lilly2$3,867
Blue Earth Diagnostics2$2,642
Tolmar, Inc.1$1,800
Shionogi Inc1$1,370
Tolmar Pharmaceuticals, Inc.1$1,300
Boston Scientific1$1,250
Myovant Sciences Inc.1$775
Medivation LLC.1$244
Angiodynamics, Inc.2$200
EDAP Technomed Inc3$42
Dendreon Pharmaceuticals LLC1$30

How this compares

$10,335,111 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York →

Medicare billing

Part B allowed, 2024
$150,149
Medicare patients
231
Services billed
930

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New York

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →